HER-2 negative

P2, N=31, Active, not recruiting, Xijing Hospital | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Jul 2028

P2, N=58, Recruiting, Fudan University

P2, N=102, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting

Patients were divided into three groups: Group A (n=69, palbociclib 125 mg orally, 3 weeks on/1 week off, plus fulvestrant), Group B (n=72, ribociclib 600 mg orally, 3 weeks on/1 week off, plus fulvestrant), Group C (n=99, abemaciclib 150 mg orally, twice daily, plus fulvestrant). However, neither drug exhibits comprehensive superiority across all endpoints. Therefore, clinical treatment decisions should take consideration of multiple factors based on individualized medicine protocol.

Unlike the canonical activation of PAR1 by thrombin, which enhances cell proliferation via mechanistic target of rapamycin (mTOR) signaling, HAP-induced noncanonical activation downregulates mTOR activation and triggers autophagy in both estrogen receptor positive/ progesterone receptor positive/ HER2 negative (ER+/PR+/HER2-) and triple negative (ER-/PR-/HER2-) breast cancer cells...Importantly, the lack of PAR1 expression in normal, healthy breast epithelial cells facilitates the peptide to selectively target breast cancer cells with relatively high PAR1 expression, highlighting its potential as a therapeutic agent against low-grade malignant breast tumor. These findings provide valuable insights into autophagy activation by a synthetic peptide that targets breast cancer cells with high PAR1 expression and for the first time shows peptide mediated targeted therapy of low-grade malignant breast tumor.

In principle, the most effective and tolerable drugs should be used first with the goals of delaying chemotherapy and offering patients the best quality and duration of life. This review aims to explain the evolving treatment landscape for HR+HER2- advanced breast cancer and provides the scientific background for developing future treatment algorithms driven by preclinical and clinical results.

P1, N=66, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

Promoter-proximal signature regions provided biological insight into tumor phenotypes. This tissue-anchored, platform-translatable framework demonstrates the feasibility of accurate, reproducible cfDNA methylation-based molecular classification in mBC.

Preoperative DOS for gastric cancer with ELM yielded unprecedentedly favorable 3-year survival outcomes and was considered a provisional standard of care without a phase III trial within our JCOG community.

P1, N=33, Completed, BeOne Medicines | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Apr 2026

P2, N=170, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting

P1/2, N=226, Terminated, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Terminated; Lack of clinical benefit